Ranked by reported Q1 2026 13F market value
Share of total reported institutional value in FDMT held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | JANUS HENDERSON GROUP PLC | 5.2M | $48.9M | +13.2% | 10.038% | 0.02% |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 5.0M | $47.0M | -10.7% | 9.660% | 0.50% |
| 3 | GOLDMAN SACHS GROUP INC | 4.2M | $39.2M | -2.3% | 8.045% |
Filings activity in FDMT during Q1 2026, grouped by how each filer changed its position.
8 quarters of 13F filings · Δ columns show change vs prior quarter
| Quarter | Inst. Holders | Δ Holders | Ownership % | Δ Ownership | Total 13F Value | Δ Value |
|---|---|---|---|---|---|---|
| Q1 2026 | 143 | 5.3% | 95.00% | +8.45 pp | $439M | +9.8% |
| Q4 2025 | 151 | +17% | 86.55% | +12.39 pp | $399M | +17% |
| Q3 2025 | 129 | +6.6% | 74.16% | +42.29 pp | $342M | +133% |
| Q2 2025 | 121 | 3.2% | 31.87% | +2.31 pp | $147M | +7.8% |
| Q1 2025 | 125 | 14% | 29.56% | 25.66 pp | $136M | 46% |
| Q4 2024 | 146 | +5.0% |
Quick answers to the most common questions about buying FDMT stock.
Based on Q1 2026 13F filings, institutional ownership of 4D Molecular Therapeutics, Inc. stands at 95.0%, held across 143 reporting institutions.
JANUS HENDERSON GROUP PLC is the largest reported institutional holder of FDMT, with approximately 5,247,151 shares worth $0.05B as of Q1 2026.
Yes — 2 widely-followed marquee investors appear among the top 25 institutional holders of FDMT, including RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC.
Our composite Smart Money Score for FDMT is 59 out of 100 (Neutral). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
| 0.00% |
| 4 | BlackRock, Inc. | 4.1M | $38.6M | +2.0% | 7.930% | 0.00% |
| 5 | Novo Holdings A/S | 3.7M | $34.0M | 0.0% | 6.984% | 2.75% |
| 6 | BVF INC/IL | 2.9M | $26.8M | -37.8% | 5.508% | 0.85% |
| 7 | STATE STREET CORP | 2.7M | $25.2M | +0.7% | 5.180% | 0.00% |
| 8 | ARMISTICE CAPITAL, LLC | 2.0M | $18.6M | +3.3% | 3.826% | 0.55% |
| 9 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.6M | $14.9M | +30.0% | 3.071% | 0.02% |
| 10 | FEDERATED HERMES, INC. | 1.4M | $13.3M | -11.0% | 2.740% | 0.02% |
| 11 | Trails Edge Capital Partners, LP | 1.3M | $12.1M | — | 2.492% | 2.78% |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 1.1M | $9.9M | +5.3% | 2.038% | 0.00% |
| 13 | BANK OF AMERICA CORP /DE/ | 974K | $9.1M | +17.0% | 1.864% | 0.00% |
| 14 | Evergreen Quality Fund GP, Ltd. | 951K | $8.9M | 0.0% | 1.820% | 0.20% |
| 15 | DEUTSCHE BANK AG\ | 708K | $6.6M | +0.5% | 1.355% | 0.00% |
| 16 | RENAISSANCE TECHNOLOGIES LLC | 578K | $5.4M | +12.7% | 1.106% | 0.01% |
| 17 | Nuveen, LLC | 562K | $5.2M | +253.8% | 1.075% | 0.00% |
| 18 | Parkman Healthcare Partners LLC | 523K | $4.9M | +3.8% | 1.000% | 0.50% |
| 19 | DIMENSIONAL FUND ADVISORS LP | 523K | $4.9M | +77.3% | 1.000% | 0.00% |
| 20 | RTW INVESTMENTS, LP | 476K | $4.4M | 0.0% | 0.910% | 0.04% |
| 21 | Propel Bio Management, LLC | 380K | $3.6M | — | 0.728% | 2.26% |
| 22 | MORGAN STANLEY | 345K | $3.2M | -48.6% | 0.661% | 0.00% |
| 23 | NORTHERN TRUST CORP | 342K | $3.2M | +9.0% | 0.654% | 0.00% |
| 24 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 328K | $3.1M | -7.1% | 0.628% | 0.00% |
| 25 | CITADEL ADVISORS LLC | 317K | $3.0M | — | 0.607% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in FDMT — a direct measure of their conviction.
| 55.22% |
| 79.17 pp |
| $255M |
| 59% |
| Q3 2024 | 139 | 3.5% | 134.39% | 65.60 pp | $620M | 48% |
| Q2 2024 | 144 | — | 199.99% | — | $1.20B | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
25 institutions opened new positions in FDMT during Q1 2026, while 33 fully exited. 91 added to existing positions and 25 trimmed.
FDMT institutional ownership rose by 8.45 percentage points quarter-over-quarter, with a net change of -8 holders.
The top 10 institutions account for 69.9% of all reported 13F value in FDMT, and the top 25 account for 89.8%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
4D Molecular Therapeutics, Inc. (FDMT) Institutional Ownership